Skip to content
PeerVoice Internal Medicine Video cover art

All episodes

PeerVoice Internal Medicine Video, 355 episodes. Page 1 of 4.

#
Title
1

Tara Iyer, MD, DABOM, MSCP - Choices, Risks, and Relief: An Expert Debate on Modern Menopause Management

2

Cristina Granziera, MD, PhD / Jiwon Oh, MD, PhD, FRCPC - Recognising Progression Beyond Relapse: Clinical Challenges and Emerging Approaches in Progressive MS

3

Roberto Pecoits-Filho, MD, PhD - Inside the Trials Driving Innovation in CKD: What Makes eGFR-Based Endpoints Clinically Meaningful?

4

Zosia Piotrowska, MD, MHS - Exploring the Evolving Landscape of HER2-Mutant NSCLC: Placing the Patient at the Center of Care Throughout Their Individual Treatment Journey

5

Sheila Wijayasinghe, MD, CCFP, MSCP - Where Change Begins: Why and How the Power of Primary Care Can Combat the Disruptive Symptoms of Menopause

6

Laura Ruth Alder, MD / Puneeth Iyengar, MD, PhD / Pooja Karukonda, MD - Shifting the Status Quo in LS-SCLC: The Practicalities of Integrating Immunotherapy Into Treatment Pathways

7

Eileen M. O'Reilly, MD, FASCO - Hope Is on the Horizon: Anticipating Novel Treatment Approaches in Advanced Pancreatic Cancer

8

Chongbo Zhao, MD - 探索不断变化的 CIDP 治疗格局:专家视角下的补体抑制疗法治疗潜力

9

Laure Gossec, MD, PhD - Why Go Head-to-Head? How Comparative Trials Shape Today’s PsA Treatment Landscape - and Tomorrow’s

10

Eric Van Cutsem, MD, PhD - Biology that Transcends Tumour Type: Integrating Tumour-Agnostic With Tumour-Specific Treatments for HER2-Positive Gastrointestinal Cancers

11

Richard Lafayette, MD, FACP - A Case-Based Masterclass Series: Guidelines to Practice in the Management of IgAN

12

Hannele Yki-Järvinen, MD, FRCP - Recognising and Referring Individuals With MASH: Practical Pathways for Our Endocrinology Practices

13

Luis Querol, MD, PhD - CIDP at a Crossroads: Addressing the Burden of Suboptimal Care and the Need for Therapeutic Advancement

14

Amarnath Challapalli, MBBS, MD (RT), MRCP, FRCR, PhD, FRCP / Amer Durrani, FRCS (Plast) - Partnering With Patients in High-Risk CSCC: Redefining the Surgical Paradigm to Optimise Clinical and Patient Outcomes

15

Meletios Dimopoulos, MD - Individualisation Requires Communication: Working With Our Patients With Newly Diagnosed Multiple Myeloma (NDMM) to Optimise Treatment Outcomes

16

Jürgen Floege, MD / Richard Lafayette, MD, FACP - Strategies to Success in IgAN Management: Harmonizing the Latest Evidence and Guidance to Maximize the Potential of Foundation Treatment Strategies

17

John Friedewald, MD, FASN, FAST - Breakthroughs and Buzz From Boston: Key Takeaways for the Kidney Transplant Community

18

Kausik Ray, MD, MPhil (Cantab), FMedSci - Altering the Disease Trajectory in Patients With and at High Risk of Atherosclerotic Cardiovascular Disease: Ensuring Best Practices for Identification and Management

19

One Disease, Many Clinical Presentations: Why and How to Spot Acute Hepatic Porphyria in Different Healthcare Settings

20

Kieran McCafferty, MB BChir, MD(Res), FRCP - Harnessing the Power of UACR to Shape the Future of CKD Management

21

Carel le Roux, MBChB, MSc, PhD - Beyond BMI: Transforming Modern Weight Management for Heart, Kidney, and Metabolic Health

22

Hannele Yki-Järvinen, MD, FRCP - MASH Matters – and It’s More Than Just a Metabolic Disease

23

Andrea Necchi, MD - Working With Our Patients as a Member of the MDT: A Bladder Cancer Awareness Month 2026 CME Initiative

24

David Alain Wohl, MD - From Guidelines to Ground Truth: The Reality of Rapid ART in the Real World

25

Javier Cortés, MD, PhD / Laura Huppert, MD - Novel Uses for Trusted Tools: Investigational Approaches for TROP2-Directed ADCs in Advanced Breast Cancer

26

Georgios Tsivgoulis, MD, PhD, MSc - Navigating the Latest Evidence Surrounding Current and Emerging Strategies for Secondary Stroke Prevention

27

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

28

Martin Köbel, MD - Scoring Folate Receptor-Alpha Expression in Gynecological Cancers: An Interactive Pathology Masterclass

29

Sven Francque, MD, PhD - The Gastroenterologist’s Guide to Finding and Managing MASH With Fibrosis: Practical Strategies for Everyday Practice

30

Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional

31

Irina Turchin, MD, FRCPC, DABD / Hélène Veillette, MD, FRCPC - On the Case: Practical Insights to Individualize Biologic Treatment in Moderate-to-Severe Hidradenitis Suppurativa

32

Colin M. Dayan, MA, MBBS, FRCP, PhD - Innovation Through Immunomodulation: The Practicalities of Delaying the Progression of Type 1 Diabetes

33

Javier Ampuero, MD, PhD - Making MASH a Priority in Our Gastroenterology Practices: Why We Should and How We Can

34

Jonathan Barratt, PhD, FRCP - From Mechanisms to Action: Exploring the Therapeutic Potential of Complement Inhibition in IgA Nephropathy

35

Austin Kulasekararaj, MD, MRCP, FRCPath - From Life-Threatening to Life-Optimised: The Evolving Management of Paroxysmal Nocturnal Haemoglobinuria Across the Complement Cascade

36

Ashkan Shoamanesh, MD, FRCPC - Turning Pathophysiologic Promise Into Evidence-Based Potential: Are Factor XIa Inhibitors Ready for Prime Time in Secondary Stroke Prevention?

37

David Kavanagh, MBChB, PhD, FRCP - A Clinically Considered Real-World Case Series: Practice Essentials From Biopsy To Diagnosis in Immune-Mediated Glomerular Diseases

38

Cristina Saura Manich, MD, PhD - First-Line Treatment of HER2-Positive Metastatic Breast Cancer: Could Investigational Approaches Improve on Current Standard of Care?

39

Yohei Doi, MD, PhD - Know the Risk, Act on Evidence: Strategic Interventions in COVID-19 Care of High-Risk Patients

40

Ira Goldberg, MD - Mastering the Fundamentals of Care for Chylomicronemia: Following the Patient Care Pathway From Differential Diagnosis to Modern Management

41

Sara Mariotto, MD, PhD - Beyond Myasthenia Gravis: What Are We Learning About FcRn Inhibitors in Other Rare Neuroimmunological Disorders?

42

Jörn M. Schattenberg, MD - Cases in Contemporary MASH Management: Expert Insights on the Practical Integration of Disease-Specific Pharmacotherapy

43

Ira Goldberg, MD - The Expanding Treatment Landscape for Familial Chylomicronemia Syndrome: Exploring New Options and Opportunities

44

Naim Alkhouri, MD, FAASLD, DABOM - Don’t Wait, and Look Beyond Weight: The Growing Case for Urgent and Comprehensive Management of MASH

45

Kris V. Kowdley, MD - Advancing the Management of Cholestatic Liver Disease: Optimizing Treatment Pathways and Novel Therapies

46

Francesco Passamonti, MD - Myelofibrosis Under the Microscope: Exploring p53 Dysregulation as a Potential Therapeutic Target

47

Erwan Donal, MD, PhD / Nina Ajmone Marsan, MD, PhD - At the Cutting Edge of ATTR-CM: How Can We Leverage Advances in Multimodality Cardiac Imaging and Artificial Intelligence to Modernise Diagnosis and Monitoring?

48

Carla M. Nester, MD, MSA, FASN - 2025 Congress Highlights From Houston, Texas: Translating C3G and IC-MPGN Trials to Treatment in an Era of Complement Inhibition

49

Jonathan Barratt, PhD, FRCP - 2025 Congress Highlights From Houston, Texas: Breaking Down the Data Driving Therapeutic Developments in IgA Nephropathy

50

Jonathan Barratt, PhD, FRCP - 2025 Congress Highlights From Houston, Texas: A Fresh Look at the Data Driving Targeted Therapeutic Developments in IgA Nephropathy

51

David Alain Wohl, MD - Inpatient Management of SARS-CoV-2 Infection: Applying Learnings From Real World Evidence to Real World Practice

52

Nancy Carteron, MD, FACR - Congress Insights Direct From Chicago: The Need-to-Knows on B Cell–Targeting in Sjögren’s Disease

53

Mike Sharma, MD, MSc, FRCPC - Challenging the Status Quo in Secondary Stroke Prevention: Current Perspectives on the Potential of Factor XIa Inhibition

54

James F. Howard Jr, MD - Direct From San Francisco: Emerging Data and Expert Perspectives on Targeted Therapies for gMG

55

Francesco Cappelli, MD, PhD - Meaningful Data From Madrid: Expanding Our Understanding of Phase 3s and OLEs in ATTR-CM

56

Emer Joyce, MB BCh BAO, PhD - Staying Ahead of the Curve in ATTR-CM: Adapting and Advancing Our Approach to Decision-Making as the Treatment Landscape Evolves

57

Sanjay Popat, FRCP, PhD - Don’t Forget About HER2: Clinical Insights and Novel Therapies for HER2-Mutant NSCLC From ESMO 2025

58

Alice M. Turner, MBChB, PhD - Cross-Talk Between Lung and Liver in Alpha-1 Antitrypsin Deficiency: A Call for Integrated Care

59

Nadia Harbeck, MD, PhD - Antibody-Drug Conjugates in Breast Cancer: Keeping Abreast of the Latest Data As They Emerge From ESMO

60

Fred Saad, MD, FRCS - From Platform to Practice: Insights From ESMO 2025 on the Latest Data Guiding Contemporary Care in mHSPC and nmCRPC

61

Suxia Wang, MD - Expert Perspective on the Diagnostic Pathways for Glomerular Diseases

62

Patrick Vermersch, MD, PhD - Stripped Back: CNS Inflammation and the Potential for Meaningful Therapeutic Progress in Non-Relapsing Forms of Multiple Sclerosis

63

Jonathan Barratt, PhD, FRCP - Preserve and Prevent: Expert Perspectives on Optimizing Outcomes in Patients With IgAN

64

Solange Peters, MD, PhD - Pioneering Precision: A Real-World Roadmap to Optimal Outcomes in NTRK Fusion-Positive and HER2-Mutant Advanced NSCLC

65

Alicia K. Morgans, MD, MPH - Clinical Conversations in Castration-Resistant Prostate Cancer: Best Practices in Discussing Testing and Treatment With Patients

66

Amber S. Podoll, MD, FASN - Stepping Up Kidney Protection in Patients With Lupus Nephritis: When and How?

67

Jonathan Barratt, PhD, FRCP - The Gut–Kidney Axis and Beyond in IgA Nephropathy: A New Frontier in Precision Therapy

68

Eva Diehl - Wiesenecker, MD - Rare Causes of Abdominal Pain: Differential Diagnosis of Uncommon but Diagnosable Causes in the Emergency Room

69

Alberto Ortiz, MD, PhD - Rare, Complex, and Life-Threatening: Recognizing and Responding to Atypical Hemolytic Uremic Syndrome

70

Richard A. Lewis, MD - Navigating the Evolving CIDP Treatment Landscape: Expert Perspectives on the Therapeutic Potential of Complement Inhibition

71

Thanai Pongdee, MD - From Diagnosis to Treatment Escalation: Improving Outcomes Across the Patient Journey in Indolent Systemic Mastocytosis

72

Jonathan Barratt, PhD, FRCP - The Nephrology Journal Club: B-Cell Modulators and eGFR Endpoints in IgA Nephropathy

73

Neal Shore, MD, FACS - Redefining Expectations in mHSPC: Options and Opportunities Across the Spectrum of Disease

74

Howard Trachtman, MD - Pioneering Progress In Focal Segmental Glomerulosclerosis: Time is Ticking To Save The Nephron

75

Lorenza Rimassa, MD - Shifting the Paradigm in Biliary Tract Cancers: Contemporary Data and Decision-Making

76

Diana L. Bitner, MD, MSCP, FACOG - Let’s Replace Silence With Science: Patient and Provider Perspectives on Addressing the Substantial Impact of Menopausal Symptoms

77

Dirk R. J. Kuypers, MD, PhD - Predicting and Achieving Long-Term Graft Survival in Solid Organ Transplant Recipients: On Track or a Challenge Too Far?

78

Angela Kay Fitch, MD, FACP, MFOMA - Separating Signal From Noise: Overcoming the Challenges of Obesity Management in Real-World Clinical Practice

79

Saiju Jacob, MD, DPhil, FRCP, FAAN - The Value of Disease Control in gMG: The Latest Data Evaluating Patient Needs and Treatment Outcomes as They Emerge From Helsinki

80

Andrea Delrue, MD, FRCPC, MPLc - Advancing Diabetes Care: Integrating Newer Basal Insulin Formulations Into Clinical Practice

81

Alison Birtle, FRCP, FRCR, MD - Case Study Challenge in Advanced Bladder Cancer: Tailoring Treatment to Individual Patients

82

Laurent Servais, MD, PhD - Eligible for Gene Therapy? The Complexity and Therapeutic Implications of Anti-AAV Antibodies

83

Liz Lightstone, MBBS (Hons), PhD, FRCP - Preventing Flare and Protecting Function: What Progress Is Being Made in Active Lupus Nephritis?

84

Anna Maria Geretti, MD, PhD - Understanding an Individual’s Readiness for Long-Acting Injectable Therapy

85

Adam Brufsky, MD, PhD / Rebecca Dent, MD, FRCP (Canada) - Same Class, Different Agents: Practical Considerations for Managing Toxicities of Interest in Patients on TROP2-Directed Therapies in Breast Cancer

86

Marianna Fontana, MD, PhD / Julian Gillmore, MD, PhD, FRCP, FRCPath - Identifying Outcomes That Matter in ATTR-CM: Critical Considerations in the Interpretation of Contemporary Clinical Trials

87

Luis Querol, MD, PhD - 2025 Congress Highlights From Edinburgh, Scotland: Breaking Down the Data Driving Novel Therapeutic Developments in CIDP

88

Ashkan Shoamanesh, MD, FRCPC - Can We Find a New Way Forward in Secondary Stroke Prevention? Exploring the Rationale and Potential Roles for Factor XIa Inhibition

89

Irina Turchin, MD, FRCPC, DABD / Hélène Veillette, MD, FRCPC - Addressing the Clinical Needs for Hidradenitis Suppurativa: How Advancements in Care Can Elevate Outcomes

90

Nicoletta Policek, PhD - When You Are Not an HIV Specialist But You Are Addressing Broader Healthcare Needs of Individuals With HIV: What Do You Need to Know?

91

Richard David Graham Leslie, MD, FRCP, FAoP - When Could Dysglycaemia in Adults Be Type 1 Diabetes? Expert Perspectives on Recognising and Addressing Diagnostic Complexities and Challenges

92

Marla C. Dubinsky, MD / David T. Rubin, MD - TNF Inhibitors in Inflammatory Bowel Disease: How Can We Realize Opportunities to Optimize Clinical and Patient Outcomes?

93

Maria Dall'Era, MD - When They Need Targeted Therapy: Selecting the Optimal Treatment Approach for Lupus Nephritis in an Evolving Treatment Landscape

94

Thomas Dörner, MD - B-Cell Depletion for Autoimmune Rheumatic Diseases: Expert Perspectives of This Mechanistic Therapeutic Approach in Clinical Context

95

Chloe E. Atreya, MD, PhD / Marwan Fakih, MD - Focusing on the Patient in Front of Us: Expert Perspectives on Providing Patient-Centered Care for Refractory Metastatic Colorectal Cancer

96

Bradley P. Dixon, MD, FASN / Carla M. Nester, MD, MSA, FASN - Getting to the Root of the Problem: Unlocking the Potential of Novel Complement Inhibitors in C3G and IC-MPGN

97

Robert J. Motzer, MD - Advanced Renal Cell Carcinoma: Clinical Advances in Approaches to Combination Therapy

98

Nicholas J. Silvestri, MD, FAAN - From Established to Emerging Therapies: Expert Perspectives on the Latest Evidence Base on FcRn Inhibitors for gMG

99

Diana N. Ionescu, MD - To Target We Need to Test: Why and How to Identify Folate Receptor Alpha-Positive Ovarian Cancer

100

Carla M. Nester, MD, MSA, FASN - Closing the Diagnostic Gap: Quick Fire Essentials in C3G and IC-MPGN